FATE THERAPEUTICS INC Revenue
FATE THERAPEUTICS INC (FATE) reported Revenue of $2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- FATE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $2.08M, a 9.18% increase year-over-year.
- FATE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $1.30M, a 20.26% decline year-over-year.
- FATE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $1.37M, a 26.40% decline year-over-year.
- FATE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.74M, a 43.36% decline year-over-year.
- FATE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for fiscal 2025 was $6.65M, a 51.24% decline from fiscal 2024.
- FATE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for fiscal 2024 was $13.63M, a 78.55% decline from fiscal 2023.
- FATE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for fiscal 2023 was $63.53M, a 34.03% decline from fiscal 2022.
- FATE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for fiscal 2022 was $96.30M, a 72.44% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-08-13 | $3.38M 10-Q · filed 2026-08-13 | $4.75M derived: sum of 3 quarters · filed 2026-08-13 | $6.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-13 | $2.67M derived: sum of 2 quarters · filed 2026-05-13 | $4.41M derived: sum of 3 quarters · filed 2026-05-13 | $6.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.11M derived: sum of 2 quarters · filed 2026-02-26 | $5.02M derived: sum of 3 quarters · filed 2026-08-13 | $6.65M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.74M 10-Q · filed 2025-11-13 | $3.65M derived: sum of 2 quarters · filed 2026-08-13 | $5.28M 10-Q · filed 2025-11-13 | $7.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.91M 10-Q · filed 2026-08-13 | $3.54M 10-Q · filed 2026-08-13 | $5.40M derived: sum of 3 quarters · filed 2026-08-13 | $8.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.63M 10-Q · filed 2026-05-13 | $3.49M derived: sum of 2 quarters · filed 2026-05-13 | $6.56M derived: sum of 3 quarters · filed 2026-05-13 | $13.34M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.93M derived: sum of 2 quarters · filed 2026-02-26 | $11.71M derived: sum of 3 quarters · filed 2026-02-26 | $13.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.07M 10-Q · filed 2025-11-13 | $9.85M derived: sum of 2 quarters · filed 2025-11-13 | $11.77M 10-Q · filed 2025-11-13 | $13.45M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $6.77M 10-Q · filed 2025-08-12 | $8.70M 10-Q · filed 2025-08-12 | $10.37M derived: sum of 3 quarters · filed 2025-08-12 | $12.32M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.93M 10-Q · filed 2025-05-13 | $3.60M derived: sum of 2 quarters · filed 2025-05-13 | $5.54M derived: sum of 3 quarters · filed 2025-05-13 | $6.48M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $3.62M derived: sum of 2 quarters · filed 2025-03-05 | $4.55M derived: sum of 3 quarters · filed 2025-03-05 | $63.53M 10-K · filed 2025-03-05 |
| 2023-09-30 | $1.94M 10-Q · filed 2024-11-12 | $2.88M derived: sum of 2 quarters · filed 2024-11-12 | $61.86M 10-Q · filed 2024-11-12 | $106.21M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $933.00K 10-Q · filed 2024-08-13 | $59.91M 10-Q · filed 2024-08-13 | $104.27M derived: sum of 3 quarters · filed 2024-08-13 | $119.25M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $58.98M 10-Q · filed 2024-05-09 | $103.34M derived: sum of 2 quarters · filed 2024-05-09 | $118.32M derived: sum of 3 quarters · filed 2024-05-09 | $136.87M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $44.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $59.34M derived: sum of 2 quarters · filed 2024-02-26 | $77.89M derived: sum of 3 quarters · filed 2024-02-26 | $96.30M 10-K · filed 2024-02-26 |
| 2022-09-30 | $14.98M 10-Q · filed 2023-11-08 | $33.53M derived: sum of 2 quarters · filed 2023-11-08 | $51.94M 10-Q · filed 2023-11-08 | $69.01M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $18.55M 10-Q · filed 2023-08-08 | $36.96M 10-Q · filed 2023-08-08 | $54.03M derived: sum of 3 quarters · filed 2023-08-08 | $68.26M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $18.41M 10-Q · filed 2023-05-03 | $35.48M derived: sum of 2 quarters · filed 2023-05-03 | $49.71M derived: sum of 3 quarters · filed 2023-05-03 | $63.12M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $17.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $31.29M derived: sum of 2 quarters · filed 2023-02-28 | $44.71M derived: sum of 3 quarters · filed 2023-02-28 | $55.85M 10-K · filed 2023-02-28 |
| 2021-09-30 | $14.22M 10-Q · filed 2022-11-03 | $27.64M derived: sum of 2 quarters · filed 2022-11-03 | $38.78M 10-Q · filed 2022-11-03 | $54.67M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $13.41M 10-Q · filed 2022-08-03 | $24.55M 10-Q · filed 2022-08-03 | $40.45M derived: sum of 3 quarters · filed 2023-02-28 | $48.01M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $11.14M 10-Q · filed 2022-05-04 | $27.04M derived: sum of 2 quarters · filed 2023-02-28 | $34.60M derived: sum of 3 quarters · filed 2023-02-28 | $40.06M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $15.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $23.45M derived: sum of 2 quarters · filed 2023-02-28 | $28.92M derived: sum of 3 quarters · filed 2023-02-28 | $31.43M 10-K · filed 2023-02-28 |
| 2020-09-30 | $7.56M 10-Q · filed 2021-11-04 | $13.02M derived: sum of 2 quarters · filed 2021-11-04 | $15.54M 10-Q · filed 2021-11-04 | $18.34M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $5.46M 10-Q · filed 2021-08-04 | $7.98M 10-Q · filed 2021-08-04 | $10.78M derived: sum of 3 quarters · filed 2021-08-04 | $13.21M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $2.52M 10-Q · filed 2021-05-05 | $5.32M derived: sum of 2 quarters · filed 2021-05-05 | $7.75M derived: sum of 3 quarters · filed 2021-05-05 | $10.56M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $2.80M 10-K · filed 2020-03-02 | $5.23M derived: sum of 2 quarters · filed 2020-11-05 | $8.05M derived: sum of 3 quarters · filed 2020-11-05 | $10.68M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.43M 10-Q · filed 2020-11-05 | $5.25M derived: sum of 2 quarters · filed 2020-11-05 | $7.88M 10-Q · filed 2020-11-05 | $9.54M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $2.82M 10-Q · filed 2020-08-05 | $5.45M 10-Q · filed 2020-08-05 | $7.11M derived: sum of 3 quarters · filed 2020-08-05 | $8.14M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $2.63M 10-Q · filed 2020-05-11 | $4.29M derived: sum of 2 quarters · filed 2020-05-11 | $5.32M derived: sum of 3 quarters · filed 2020-05-11 | $6.35M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $1.66M 10-K · filed 2020-03-02 | $2.69M derived: sum of 2 quarters · filed 2020-03-02 | $3.71M derived: sum of 3 quarters · filed 2020-03-02 | $4.74M 10-K · filed 2021-02-24 |
| 2018-09-30 | $1.03M 10-K · filed 2020-03-02 | $2.05M derived: sum of 2 quarters · filed 2020-03-02 | $3.08M 10-Q · filed 2019-11-05 | $4.11M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $1.03M 10-K · filed 2020-03-02 | $2.05M 10-Q · filed 2019-08-06 | $3.08M derived: sum of 3 quarters · filed 2020-03-02 | $4.11M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $1.03M 10-K · filed 2020-03-02 | $2.05M derived: sum of 2 quarters · filed 2020-03-02 | $3.08M derived: sum of 3 quarters · filed 2020-03-02 | $4.11M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $1.03M 10-K · filed 2019-03-05 | $2.05M derived: sum of 2 quarters · filed 2019-03-05 | $3.08M derived: sum of 3 quarters · filed 2019-03-05 | $4.11M 10-K · filed 2020-03-02 |
| 2017-09-30 | $1.03M 10-K · filed 2019-03-05 | $2.05M derived: sum of 2 quarters · filed 2019-03-05 | $3.08M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $1.03M 10-K · filed 2019-03-05 | $2.05M 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | $1.03M 10-K · filed 2019-03-05 | |||
| 2016-12-31 | $4.40M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |